vimarsana.com
Home
Live Updates
Basilea Pharmaceutica AG: Basilea to become a leading anti-infectives company backed by strong financial results 2021 : vimarsana.com
Basilea Pharmaceutica AG: Basilea to become a leading anti-infectives company backed by strong financial results 2021
65% year-on-year growth in non-deferred revenue from Cresemba and Zevtera Operating profit of CHF 1.2 million Future strategic focus on anti-infectives Exploring strategic options to maximize the value
Related Keywords
China ,
Germany ,
Japan ,
United States ,
Basilea ,
Basel Stadt ,
Switzerland ,
Swiss ,
Nils Schr ,
Asahi Kasei Pharma ,
David Veitch ,
Nicole Onetto ,
Thomas Werner ,
Domenico Scala ,
Cresemba Zevtera ,
Martin Nicklasson ,
Leonard Kruimer ,
Adesh Kaul ,
Stevend Skolsky ,
Head Of Corporate Communications Investor Relations ,
Arqule Inc ,
Merck Co Inc ,
Pfizer ,
Wellcome ,
Biomedical Advanced Research ,
Human Services ,
Us Department Of Health ,
Drug Administration ,
Development Authority ,
Swiss Exchange ,
Basilea Pharmaceutica Ltd ,
Germany Federal Ministry Of Education ,
Office Of The ,
National Medical Products Administration ,
Agreement Number ,
Chief Executive Officer ,
Chief Financial Officer ,
Basilea Pharmaceutica ,
Drug Approval Licenses ,
Drug Evaluation ,
New Drug Application ,
Orphan Drug Designation ,
Investigational New Drug ,
Corporate Communications ,
Investor Relations ,
Assistant Secretary ,
Cooperative Agreement Number ,
Wellcome Trust ,
Federal Ministry ,
Clinical Oncology ,
Pharmaceutica ,
Become ,
Reading ,
Anti ,
Infectives ,
Company ,
Backed ,
Strong ,
Financial ,
Results ,
021 ,
vimarsana.com © 2020. All Rights Reserved.